teichoic acid, and peptidoglycan (4 -10) . These cytokines activate multiple downstream inflammatory pathways, triggering the release of both pro-and antiinflammatory mediators, activating coagulation, and inhibiting fibrinolysis (11) (12) (13) (14) . IL-6, released in response to TNF and IL-1 (15) , is consistently detected in the blood of patients with sepsis, and elevated levels are associated with adverse outcome (16) .
Animal studies indicate that blockade of the biological activity of TNF-␣, before initiation of irreversible organ failure, improves hemodynamic status, prevents organ dysfunction, and ultimately increases survival (17) (18) (19) (20) . However, clinical trials of neutralization of TNF in human sepsis have yielded less consistent results (21) (22) (23) (24) (25) (26) . Increased levels of TNF are variably detected in the serum of septic patients (27, 28) , perhaps because of its intermittent release in sepsis and its short half-life in the systemic circulation (29) . Since the release of IL-6 can be triggered by TNF, elevated IL-6 levels may be useful in identifying those patients most likely to benefit from an anti-TNF-␣ approach (30, 31) .
Afelimomab, the F(ab') 2 fragment of a murine monoclonal antibody to human TNF-␣, effectively neutralizes TNF-␣ both in vitro and in vivo (32, 33) . In a chimpanzee model of endotoxemia, administration of afelimomab abrogated serum TNF levels and reduced serum IL-6 levels (34) . In pilot human trials in sepsis, afelimomab administration appeared to reduce mortality, particularly in patients with high baseline IL-6 serum levels (30, 35) .
We hypothesized that administration of afelimomab would reduce the rate of death from all causes at 28 days in patients with severe sepsis and elevated serum IL-6 levels as identified by a rapid IL-6 test.
METHODS
Patients. We enrolled 2,634 patients in this randomized, double-blind, placebo-controlled trial conducted at 157 centers in North America between January 6, 1996, and June 19, 1999 . The Institutional Review Boards of all participating institutions approved the protocol, and written informed consent was obtained from all enrolled patients or their proxies.
Selection Criteria. Patients were eligible for randomization if they were hospitalized, were Ն18 yrs, and met criteria for sepsis syndrome within a 24-hr period (36) : definitive microbiological or clinical evidence of acute infection; hypothermia or hyperthermia; tachycardia; tachypnea; and hypotension or other evidence of end-organ dysfunction. Treatment was initiated within 24 hrs of meeting inclusion criteria. (Appendix 1 summarizes inclusion and exclusion criteria.)
Rapid Assay of IL-6 and Treatment Assignments. Before randomization, patients were stratified according to the results of a rapid IL-6 test. The IL-6 test kit is a qualitative assay for IL-6 in human serum designed with a threshold sensitivity of approximately 1000 pg/mL (analytical sensitivity 90.4%, analytical specificity 82.2%, data on file at Abbott Laboratories, Parsippany, NJ). Patients were then randomly assigned 1:1 to receive afelimomab 1 mg/kg in a vehicle containing human serum albumin 1.5 mg/kg or placebo (vehicle alone) intravenously over 15 mins every 8 hrs for 3 days. Randomization was in blocks of four stratified by study center and IL-6 levels using a computer-generated sequence. Randomization and assignment of treatment packages took place in the pharmacy. Those involved in either delivering care or making therapeutic decisions for the patient were blinded to the results of the IL-6 test. Afelimomab was derived as a full-length monoclonal antibody from the hybridoma AM 195/8/G3 (BALB/c mice spleen cells fused with the myeloma cell line Sp2/0-Ag14) that underwent proteolytic cleavage with pepsin. The final F(ab') 2 -fragment was supplied as a lyophilisate for reconstitution in water for injection.
Evaluation of Patients. All patients were followed for 28 days after initiation of study treatment. Demographic and clinical information was assessed, and Acute Physiology and Chronic Health Evaluation II (37) and Simplified Acute Physiology Score II (38) were measured at the time of enrollment. Organ dysfunction was assessed at baseline and during the study using the Multiple Organ Dysfunction (MOD) and Sequential Organ Failure Assessment (SOFA) scores (39, 40) .
A Clinical Evaluation Committee, using prospectively defined criteria, evaluated the case report form of each patient in a blinded fashion. Each patient was classified according to primary source of infection, primary causative organisms, adequacy of antimicrobial therapy, adequacy of surgical source control, adequacy of adjunctive support measures (defined as a composite of adequate hemodynamic, respiratory, and nutritional support), and adherence to protocol.
Serum Cytokine Levels. Serum TNF levels (TNF-EASIA, Biosource International) and IL-6 levels (IL-6 EASIA, Biosource International) were assessed at baseline in all randomized patients. Serum samples obtained at baseline and 8, 24, 48, and 72 hrs were assayed for sequential serum IL-6 concentrations (Roche Diagnostics, Indianapolis, IN). A random sample of 300 patients, 150 each with positive and negative rapid IL-6 tests, had TNF concentrations measured (Quantikine High Sensitivity TNF Assay, R&D Systems, Minneapolis, MN) at baseline, 8 hrs, 72 hrs, and day 14. At baseline, day 14 and day 28 serum samples were analyzed for antimurine antibodies (ImmuSTRIP HAMA IgG, Immunomedics).
Data Safety Monitoring Board and Interim Analysis. A Data Safety Monitoring Board periodically reviewed unblinded patient safety data and was able to recommend that accrual be stopped in the IL-6 test positive and/or the IL-6 test negative groups for safety reasons. The Data Safety Monitoring Board also performed the planned interim analysis and could recommend to the sponsor to increase the sample size of IL-6 test positive patients based on the observed placebo mortality rate or to terminate the study prematurely for efficacy or futility.
The trial was designed to enroll 500 patients with high IL-6 levels. An interim analysis was planned for efficacy, futility, and possible sample size adjustment after enrollment of 250 patients with high IL-6 levels (41-43). In addition, IL-6 test negative patients were to be randomized to assess the safety of afelimomab in that population. After the interim analysis was performed, the sample size for the IL-6 positive group was recalculated from 500 to 1,000 based on a lower than expected placebo mortality rate.
Statistical Analysis. The primary efficacy end point was all-cause mortality determined at 28 days after the first study drug infusion. The primary analysis included all patients who were randomized and received any amount of study drug in the IL-6 test positive group (intention-to-treat). The placebo and afelimomab treatment groups were compared using the likelihood-ratio test within a logistic regression model with all variables listed in the statistical plan. These variables included baseline disease characteristics (Simplified Acute Physiology Score II predicted mortality risk and MOD and SOFA scores) (39, 40, 44) , mode of acquisition and type of infection, time from onset of sepsis to first study dose, demographics (age, race, gender), center effects (ICU type and country), and baseline cytokine levels (IL-6, IL-8, and TNF). Because of the inclusion of an interim analysis, the level of significance was adjusted to 0.0452 for the primary end point (42) . Changes from baseline levels of serum IL-6 and organ dysfunction (both MOD and SOFA scores) were analyzed using the Wilcoxon rank sum test to test for differences between groups. To confirm the primary analysis of mortality, additional statistical tests were performed using a nonparametric analysis of covariance for logistic regression (45) . An analysis for variables confounding outcome (i.e., change in the treatment odds ratio by Ն10%) was also conducted.
Patients with an IL-6 test negative result, as well as all randomized patients, were also analyzed for all-cause mortality at 28 days, serum cytokine levels, and organ dysfunction.
The proportions of all randomized patients who had adverse events, serious adverse events, and secondary infections were compared using the Pearson's chi-square test. All reported p values are two-sided.
RESULTS
The 157 centers participating in the trial randomized a total of 2,634 patients: 998 (37.9%) in the positive IL-6 test population and 1,636 (62.1%) in the negative IL-6 test population (Fig. 1) .
Baseline Characteristics of the Patients. The baseline characteristics of the IL-6 test positive population and the IL-6 test negative population are summarized in Table 1 , and the nature of their inciting infections is shown in Table 2 . Of the 998 patients in the IL-6 test positive group, 488 were randomized to receive treatment with afelimomab and 510 were assigned to placebo. Approximately three fourths of the test positive patients were in shock. Baseline severity of illness scores and organ failure scores were generally higher in the afelimomab group compared with placebo, with the difference in SOFA scores between the two groups approaching statistical significance (p ϭ .058). Approximately 40% of the patients were admitted to the ICU following surgery, whereas 60% had nonoperative diagnoses. Circulating TNF was detectable in most patients, and the median TNF levels were similar in both treatment groups; TNF levels were higher in IL-6 positive patients. For patients in the IL-6 positive group, median IL-6 levels were 6538 pg/mL and 5486 pg/mL in the afelimomab and placebo group, respectively, with substantial variability between individual patients. The abdomen was the most common site of infection, followed by the lung. Approximately 40% of patients were bacteremic. The prevalence of Gram-negative and Gram-positive infections was similar within and between the two treatment groups. About two thirds of the infections were communityacquired.
The Clinical Evaluation Committee evaluation of patients in the elevated IL-6 population concluded that the proportions of patients given adequate antibiotic therapy (90.2% vs. 91.6%), adequate surgical source control/nonsurgical cases (92.6% vs. 90.4%), and adequate supportive care (96.3% vs. 95.9%) were comparable in the afelimomab-and placebotreated patients, respectively.
In the 1,636 IL-6 test negative patients, fewer patients were in shock, and Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II, MOD, and SOFA scores were lower than in those patients with a positive test. The prevalence of abdominal infections was lower in the IL-6 test negative patient population. The distribution of Gram-positive and Gram-negative bacteria was similar to that seen in the IL-6 test positive population. There were fewer community-acquired and more ICU-acquired infections in the IL-6 test negative population compared with the IL-6 test positive population. Adequacy of care in the IL-6 test negative population was similar to that in the elevated IL-6 population, with 90.7% receiving adequate antibiotic therapy, 92.6% receiving adequate surgical source control or being nonsurgical, and 96.7% receiving adequate supportive care.
Mortality. The placebo mortality rate of the IL-6 test positive population was significantly higher than that of the IL-6 test negative population (47.6% vs.
28.6%, respectively). In the IL-6 test positive population, 243 of the 510 (47.6%) patients in the placebo group and 213 of 488 (43.6%) of the patients in the afelimomab group died. Using a prespecified logistic regression analysis to adjust for baseline imbalances between treatment arms, the adjusted reduction in mortality was 5.8% (p ϭ .041), and the corresponding relative risk reduction for mortality was 11.9%. The mortality odds ratio for patients with elevated IL-6 levels who received afelimomab relative to placebo was 0.744 (95% confidence interval, 0.559 -0.988, p ϭ .041, Table 3 ). Besides treatment effect, only probability of mortality based on Simplified Acute Physiology Score II score, age, mode of acquisition of infection, baseline IL-6 levels, and SOFA scores were significant factors in the model. Based on the analysis for confounders, baseline SOFA score was the only confounding variable, and the model containing treatment and SOFA yielded a nearly identical p value (p ϭ .042).
In the IL-6 test negative population (n ϭ 1636), the 28-day mortality rates for the placebo and afelimomab groups were 28.6% and 25.5%, respectively, a 3.1% reduction in mortality. In the overall population (n ϭ 2634), the 28-day mortality rates for the placebo and afelimomab groups were 35.9% and 32.3%, respectively, a 3.6% absolute reduction in mortality. Figures  2-4 show the Kaplan-Meier survival curves for the IL-6 test positive, test negative, and overall groups.
Biochemical and Physiologic Effects. Among IL-6 test positive patients, afelimomab significantly reduced TNF levels at 8 and 72 hrs compared with placebo (Fig.  5) . Similarly, IL-6 levels were significantly lower in the afelimomab-treated group at 8 hrs compared with placebo (Fig. 6) . MOD scores at days 3, 4, and 7 ( Fig. 7) and SOFA scores at days 2 and 7 ( Fig. 8) were significantly lower in patients who received afelimomab.
Safety. Adverse events were similar for afelimomab and placebo patients within the high and low IL-6 groups and are summarized in Table 4 for all patients irrespective of IL-6 test result. Afelimomab did not increase mortality in IL-6 test negative patients: 234 of 819 (28.6%) patients randomized to placebo died compared with 208 of 817 (25.5%) patients randomized to afelimomab. Treatment with afelimomab was not associated with an increase in secondary infections.
The human anti-mouse antibody formation rate was 23.6% (151 of 639) in the afelimomab group and 6.3% (38 of 601) in the placebo group. There were no clinical sequelae associated with human antimouse antibody formation.
DISCUSSION
The MONARCS trial is the largest randomized trial that has been undertaken in patients with severe sepsis. In contrast to previous trials of therapies that target TNF (21-26), our primary target population was patients with elevated IL-6 levels. We found that the administration of afelimomab lowered circulating levels of TNF and IL-6, accelerated the resolution of organ dysfunction, and reduced 28-day all-cause mortality by 5.8% (p ϭ .041) corresponding to an 11.9% relative reduction in mortality. Despite the size of the entire population of the MONARCS trial (n ϭ 2634), the target group of IL-6 test positive patients was relatively small (n ϭ 998). The predefined primary analysis plan incorporated logistic regression to reduce variability resulting from baseline imbalances between study groups and allow a more precise estimate of the true treatment effect. The difference between the crude and adjusted risk of death was the result of adjusting for random imbalances of prespecified covariates, the greatest imbalance being the difference in baseline SOFA scores between treatment groups (Table 1) .
The impact of therapy on 28-day mortality in the IL-6 positive population (4% unadjusted and 5.8% adjusted) might be perceived as modest. Early sepsis trials typically proceeded based on exaggerated estimates of therapeutic efficacy and so were underpowered to detect a smaller, although clinically important, effect. However, multiple findings of the MONARCS trial are consistent with the presumed mechanism of action of afelimomab. Thus, treatment with the antibody reduced levels of circulating TNF, a biological effect reflected in greater reduction in levels of the downstream mediator, IL-6. This biological activity resulted in significant acceleration of the resolution of organ dysfunction measured using the MOD and SOFA scores and ultimately led to a significantly higher survival rate at 28 days for treated patients.
Multiple previous studies of anti-TNF-␣ therapies have failed to find a significant mortality benefit (21) (22) (23) (24) (25) . One of the anti-TNF-␣ agents (25) evaluated showed a detrimental effect on mortality, but a metaanalysis of the results of the individual trials demonstrated a small, but significant, treatment benefit not dissimilar to that seen in the present study (46) . The design of the MONARCS trial differs from those previous studies in several ways. The MONARCS trial used more rigorous and reproducible criteria for the documentation of infection. By recruiting Ͼ2,600 study subjects, the trial had improved statistical power to demonstrate a smaller treatment sizes than prior anti-TNF trials. Moreover, we measured morbidity over the ICU stay, a potentially more sensitive measure of therapeutic benefit (47), using an organ dysfunction score. In addition, this trial used two strategies to reduce the influence of patient heterogeneity. First, patients were stratified on the basis of elevated IL-6 levels, as a biochemical marker identifying a subset of patients with a hyperinflammatory response at increased risk of death. Furthermore, the confounding influence of random baseline variability in study groups was minimized by the use of a logistic regression model (44) . Afelimomab was also administered differently, using an extended dosing schedule every 8 hrs for 72 hrs. Patients in other trials of anti-TNF-␣ therapy received a single administration of study drug. Finally, in contrast to other anti-TNF-␣ antibodies investigated, afelimomab is the F(ab')2-fragment of a murine monoclonal antibody. Fragments of antibodies may have greater tissue penetration than complete antibodies, which could enhance neutralization of TNF-␣ in tissues. Nonetheless, the overall mortality benefit in the entire population in this study was remarkably similar in magnitude to the statistically significant 3.5% reduction seen in CI, confidence interval; IL, interleukin. a Logistic regression model applied to the analysis of mortality rate adjusted for 14 covariates (Simplified Acute Physiology Score II predicted mortality risk, country, intensive care unit type, baseline IL-6, IL-8, and tumor necrosis factor, age, race, gender, mode of acquisition, organism category, time from onset to first dose, and baseline multiple organ dysfunction and Sequential Organ Failure Assessment scores).
a meta-analysis of all previous anti-TNF trials (46) .
The mortality benefit demonstrated with afelimomab occurred in the setting of a safety profile similar to that of placebo with no increase in secondary infections. The human anti-mouse antibody formation rate seen with afelimomab was lower than that seen in sepsis studies with complete murine antibodies (23, 24, 29) and was not associated with clinical sequelae.
The MONARCS study has demonstrated a clinically relevant treatment effect in sepsis patients, particularly in patients with elevated IL-6 levels. Because of the number of participating sites, the results should be generalizable to patients admitted to a contemporary ICU. Moreover, the study results are biologically consistent and show that TNF neutralization can improve survival in sepsis. Finally, because the primary efficacy analysis incorporated logistic regression, it was possible to compensate for the considerable baseline heterogeneity characteristic of this complex patient population. However, the major weaknesses of the study reflect this heterogeneity. Despite recruiting 998 patients to the predefined target population for efficacy evaluation, randomization did not achieve complete balance between study groups among clinically relevant factors. The detection of the treatment effect for afelimomab on 28-day mortality-which would have been masked by simple chisquare analysis-required more complex and less familiar statistical modeling than has traditionally been used in sepsis trials.
This study demonstrated that in patients with severe sepsis and elevated IL-6 levels, afelimomab at a dose of 1 mg/kg every 8 hrs for 3 days decreased mortality and had a safety profile similar to that of placebo. This reduction in mortality was supported by evidence of biological and physiologic effect as demonstrated by significant reductions in TNF and IL-6 levels as well as organ failure scores in patients receiving anti-TNF antibody compared with those who received placebo. tal Medical Center, Chicago, IL, Joseph
